Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Annika Loft; Andreas Kjær

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Translated title of the contribution: Nuclear medical diagnostic and cancer precision medicine

Department of Clinical Physiology and Nuclear Medicine

Abstract

Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

Translated title of the contribution	Nuclear medical diagnostic and cancer precision medicine
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	180
Issue number	46
Pages (from-to)	V06180463
ISSN	0041-5782
Publication status	Published - 12 Nov 2018

Cite this

@article{cf136d074c8b47638e01f07e98d653f5,

title = "Nuklearmedicinsk diagnostik og cancerpr{\ae}cisionsmedicin",

abstract = "Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.",

author = "Annika Loft and Andreas Kj{\ae}r",

year = "2018",

month = nov,

day = "12",

language = "Dansk",

volume = "180",

pages = "V06180463",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "46",

}

TY - JOUR

T1 - Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

AU - Loft, Annika

AU - Kjær, Andreas

PY - 2018/11/12

Y1 - 2018/11/12

N2 - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

AB - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

UR - https://www.scopus.com/pages/publications/85056322032

M3 - Tidsskriftartikel

C2 - 30417816

SN - 0041-5782

VL - 180

SP - V06180463

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 46

ER -

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Abstract

Other files and links

Fingerprint

Cite this